Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
NCT07467447 on ClinicalTrials.gov · last registry update 2026-03-12
An unusually large phase 2: 300 participants, more than double the 114 typical for the stage. Due to report 14 March 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Mean percent change in body weight from randomization/baseline to Week 24. Sponsors move these dates routinely; any movement since this site started watching is listed below. retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P2
- Drug
- retatrutide
- Sponsor
- Hudson Biotech
- Sponsor type
- Industry
- Enrollment
- 300
- Started
- 2026-02-15
- Primary completion
- 2027-03-14 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean percent change in body weight from randomization/baseline to Week 24.
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.